Bristol-based FluoretiQ was founded two years ago and has just been backed by Bristol Private Equity Club (BPEC). The company uses technology built on advances in glycan chemistry and quantum optics to identify bacterial infections in hospitals, clinics and care homes.
Chief executive, Neciah Dorh, who has a PhD in nanophotonics and a background in fluorescence technologies for bio-sensing, leads the team who have developed the techniques.
FluoretiQ was developed with venture capital from Deepbridge Capital. (InsiderMedia)
